Piper Sandler Reaffirms Overweight Rating for Sotera Health (NASDAQ:SHC)

Sotera Health (NASDAQ:SHC)‘s stock had its “overweight” rating reiterated by research analysts at Piper Sandler in a research report issued on Wednesday,Benzinga reports. They presently have a $22.00 target price on the stock, down from their previous target price of $24.00. Piper Sandler’s price target suggests a potential upside of 38.93% from the company’s previous close.

Several other brokerages have also recently weighed in on SHC. Citigroup lifted their price objective on Sotera Health from $21.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Wall Street Zen cut Sotera Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Wells Fargo & Company cut Sotera Health to an “overweight” rating in a report on Thursday, January 8th. Zacks Research cut Sotera Health from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Finally, Royal Bank Of Canada began coverage on Sotera Health in a report on Thursday, January 8th. They set an “outperform” rating and a $24.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Sotera Health Stock Performance

SHC traded up $0.51 during trading on Wednesday, hitting $15.84. The stock had a trading volume of 1,154,593 shares, compared to its average volume of 2,568,500. The company has a 50 day moving average price of $15.00 and a 200-day moving average price of $16.49. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 58.62 and a beta of 1.82. Sotera Health has a one year low of $10.80 and a one year high of $19.85. The company has a debt-to-equity ratio of 3.66, a current ratio of 2.46 and a quick ratio of 2.24.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.01. The business had revenue of $280.05 million during the quarter, compared to the consensus estimate of $270.78 million. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 EPS. Sotera Health has set its FY 2026 guidance at 0.930-1.010 EPS. As a group, research analysts predict that Sotera Health will post 0.88 EPS for the current year.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction on Friday, March 6th. The stock was sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the completion of the sale, the director owned 12,735,301 shares of the company’s stock, valued at approximately $194,468,046.27. This trade represents a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sculptor Capital LP boosted its stake in Sotera Health by 57.4% during the 4th quarter. Sculptor Capital LP now owns 21,000,000 shares of the company’s stock valued at $370,440,000 after purchasing an additional 7,658,200 shares during the last quarter. Sachem Head Capital Management LP boosted its stake in Sotera Health by 47.2% during the 4th quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company’s stock valued at $205,418,000 after purchasing an additional 3,735,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Sotera Health by 16.7% during the 4th quarter. Vanguard Group Inc. now owns 19,228,375 shares of the company’s stock valued at $339,189,000 after purchasing an additional 2,756,583 shares during the last quarter. AQR Capital Management LLC boosted its stake in Sotera Health by 1,206.2% during the 4th quarter. AQR Capital Management LLC now owns 2,864,106 shares of the company’s stock valued at $50,523,000 after purchasing an additional 2,644,831 shares during the last quarter. Finally, Norges Bank purchased a new stake in Sotera Health during the 4th quarter valued at $45,278,000. Institutional investors own 91.03% of the company’s stock.

Sotera Health News Summary

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q1 results beat consensus: Sotera reported $0.18 adjusted EPS and $280.05M revenue (up 10% YoY), topping analyst estimates — the official release highlights revenue growth, margin expansion and a return to GAAP net income. Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
• Positive Sentiment: Profitability and cash?flow metrics improved: Adjusted EBITDA rose ~10.5% and the company moved to positive net income versus a year?ago loss, supporting margin expansion narratives cited by analysts. Sotera Health Company (SHC) Surpasses Q1 Earnings and Revenue Estimates
• Positive Sentiment: Company reaffirmed FY2026 outlook and issued EPS guidance of $0.93–$1.01 and revenue guidance roughly $1.2B–$1.3B, signaling management confidence in mid?single?digit growth and margin improvement for the year. Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
• Neutral Sentiment: Planned leadership transition announced: Alton Shader will become CEO on May 26, 2026 while current CEO Michael Petras shifts to Executive Chairman — positioned as a planned succession but investors will watch execution risks. Sotera Health Announces Leadership Transition
• Neutral Sentiment: Earnings call and transcripts convey a confident tone and operational momentum; analysts and transcripts note sustained demand in sterilization and testing services but will watch unit volumes and pricing mix. Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Valuation and leverage remain potential headwinds: SHC trades at a high P/E and the company has elevated debt (high debt-to-equity), which could amplify downside if growth or margins disappoint. No article link provided

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.